Ozempic, a Diabetes Medication, Slated for India Launch This Month

Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.

Diabetes Drug Ozempic Coming to India This Month

Novo Nordisk's semaglutide portfolio in India will be completed with the launch of Ozempic, providing therapeutic options for both diabetes and obesity. This introduction follows increasing competition from Eli Lilly's Mounjaro, a US rival approved for both diabetes and weight management. Pharmarack data indicates that Lilly sold 262,000 doses of Mounjaro in October, compared to Novo's Wegovy with 26,000 doses.

Novo Nordisk already maintains a significant presence in the diabetes market in India through its Rybelsus semaglutide tablets and other offerings. According to Vishal Manchanda, an analyst from Systematix Institutional Equities, "Novo is well-positioned to promote Ozempic due to its established brand recognition in diabetes treatment."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Furthermore, Manchanda suggested that "Ozempic may potentially be prescribed for individuals experiencing infertility or sleep apnea, and for those seeking weight reduction." Health tracking apps like Shotlee can help monitor any side effects from new medications.

Source Information

Originally published by NewsBytes.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies

Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.

7 min read

Health & Wellness

Retatrutide Breaks Records: What Phase 3 TRIUMPH-1 Data Means

Eli Lilly's Retatrutide has shown remarkable weight loss potential in Phase 3 trials. We break down the TRIUMPH-1 results, safety data, and what patients can expect.

9 min read

Health & Wellness

Driving on Ozempic & Mounjaro: Avoiding the £1,000 DVLA Fine

New regulations warn that GLP-1 medication users could face significant fines if side effects impair driving. Here is the complete guide to staying safe and compliant.

8 min read

Same topic: Diabetes

All Diabetes articles →

Health & Wellness

GLP-1 Medications and Supplement Needs: What You Should Know

As GLP-1 medications gain popularity for weight loss and diabetes management, understanding their impact on nutrient absorption is crucial. This article explores the link between these powerful drugs and the rising demand for supplements, offering insights from medical professionals and research.

6 min read

Medication News

Generic Ozempic® Now Available in Canada: What You Need to Know

Apotex Inc. has launched Apo-Semaglutide Injection™, a generic version of Ozempic®, in Canada. This development brings a more affordable treatment option for type 2 diabetes management to Canadian patients and healthcare providers.

6 min read

Health & Wellness

GLP-1 Weight Loss Drugs: Usage Trends and What You Need to Know

The popularity of GLP-1 receptor agonists for weight management is soaring. This article delves into the latest trends, the science behind these medications, and essential considerations for patients and healthcare providers.

7 min read

More in Health

Weight Management

GLP-1 Weight Loss Drugs: Eli Lilly's Next-Gen Therapies vs. Novo Nordisk

The race for dominance in the lucrative weight loss drug market is intensifying. While Novo Nordisk's Wegovy has been a pioneer, Eli Lilly is rapidly advancing its pipeline with next-generation therapies poised to challenge the status quo. This article delves into the science, clinical data, and market implications of these groundbreaking treatments.

6 min read

Health & Wellness

GLP-1 Drugs: Understanding the Weight Loss Revolution

The advent of GLP-1 receptor agonists has transformed the landscape of weight management, offering new hope for individuals struggling with obesity. This article delves into the science, benefits, potential drawbacks, and the leading players in this groundbreaking field.

7 min read

Health & Wellness

Generic Semaglutide Launches in Canada: What Patients Need to Know

The Canadian market sees the arrival of a generic semaglutide injection, a significant development for individuals managing type 2 diabetes and seeking weight loss solutions. This launch by Dr. Reddy's Laboratories marks a new era of accessibility for this popular GLP-1 therapy.

7 min read